OrthoPediatrics (NASDAQ:KIDS) reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis revenue. Revenue growth led by Trauma & Deformity and OPSB“We have reached an inflection point in our financial trajectory,” Bailey said, citing revenue growth, adjusted EBITDA expansion and reduced free-cash-flow usage. Bailey said the agreement complements OrthoPediatrics’ existing Bioretec partnership and could support the company’s expansion into pediatric hand and foot procedures. Scoliosis sales affected by 7D and Brazil timingGlobal scoliosis revenue declined 9% to $16.9 million. Still, he said OrthoPediatrics expects its product-launch cycle to increasingly contribute to growth, margins and returns on capital over the next several years.